199 related articles for article (PubMed ID: 22174695)
1. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Tateno T; Asa SL; Zheng L; Mayr T; Ullrich A; Ezzat S
PLoS Genet; 2011 Dec; 7(12):e1002400. PubMed ID: 22174695
[TBL] [Abstract][Full Text] [Related]
2. FGFR4 polymorphic variants modulate phenotypic features of Cushing disease.
Nakano-Tateno T; Tateno T; Hlaing MM; Zheng L; Yoshimoto K; Yamada S; Asa SL; Ezzat S
Mol Endocrinol; 2014 Apr; 28(4):525-33. PubMed ID: 24625004
[TBL] [Abstract][Full Text] [Related]
3. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
Ezzat S; Wang R; Pintilie M; Asa SL
Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
[TBL] [Abstract][Full Text] [Related]
4. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.
Serra S; Zheng L; Hassan M; Phan AT; Woodhouse LJ; Yao JC; Ezzat S; Asa SL
Cancer Res; 2012 Nov; 72(22):5683-91. PubMed ID: 22986737
[TBL] [Abstract][Full Text] [Related]
5. Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes.
Jalali S; Monsalves E; Tateno T; Zadeh G
Endocrinology; 2016 Sep; 157(9):3577-87. PubMed ID: 27267848
[TBL] [Abstract][Full Text] [Related]
6. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract][Full Text] [Related]
7. The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.
Ezzat S; Zheng L; Florez JC; Stefan N; Mayr T; Hliang MM; Jablonski K; Harden M; Stančáková A; Laakso M; Haring HU; Ullrich A; Asa SL
Cell Metab; 2013 Jun; 17(6):929-940. PubMed ID: 23747250
[TBL] [Abstract][Full Text] [Related]
8. Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome.
Brito LP; Lerário AM; Bronstein MD; Soares IC; Mendonca BB; Fragoso MC
J Clin Endocrinol Metab; 2010 Oct; 95(10):E271-9. PubMed ID: 20660043
[TBL] [Abstract][Full Text] [Related]
9. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.
Stadler CR; Knyazev P; Bange J; Ullrich A
Cell Signal; 2006 Jun; 18(6):783-94. PubMed ID: 16109476
[TBL] [Abstract][Full Text] [Related]
10. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
12. Induction of Fibroblast Growth Factor Receptor 4 by Helicobacter pylori via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving SRC Signaling in Gastric Cancer.
Zhang X; Soutto M; Chen Z; Bhat N; Zhu S; Eissmann MF; Ernst M; Lu H; Peng D; Xu Z; El-Rifai W
Gastroenterology; 2022 Sep; 163(3):620-636.e9. PubMed ID: 35588797
[TBL] [Abstract][Full Text] [Related]
13. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu X; Zheng L; Asa SL; Ezzat S
Am J Pathol; 2010 Dec; 177(6):2860-9. PubMed ID: 21037081
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.
Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S
J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963
[TBL] [Abstract][Full Text] [Related]
16. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Chan KM; Zhou Z; Alitalo K; Taipale J; Keski-Oja J; Lehti K
Proc Natl Acad Sci U S A; 2010 Sep; 107(36):15786-91. PubMed ID: 20798051
[TBL] [Abstract][Full Text] [Related]
17. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
[TBL] [Abstract][Full Text] [Related]
18. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
[TBL] [Abstract][Full Text] [Related]
19. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
20. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
